Tag: SMA gene therapy long term outcomes 2024
Complete Guide to SMA Gene Therapy 2024 (USA): Adult Clinical Trials, Cost Per Dose, Long-Term Outcomes, Zolgensma vs Spinraza & Infant Medicaid Coverage
October 2024 updated FDA, 2023 American Academy of Neurology, and 2024 CMS data confirms approved SMA gene therapies cut type 1 infant mortality by 82%, with 8+ years of proven long-term efficacy. This official buying guide covers 2024 U.S. adult SMA gene therapy clinical trials, current cost per dose, infant Medicaid coverage rules, and head-to-head